Aardvark Therapeutics Secures USD 85 Million Oversubscribed Series C Financing
Aardvark Therapeutics, Inc. has received an USD 85 million oversubscribed Series C financing led by Decheng Capital.
Rare Pediatric Disease | 10/05/2024 | By Aishwarya | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy